Site is Being Upgraded

Xenon-based therapy for Non-alcoholic fatty liver disease (NAFLD): Xenon  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 17/October/2017, 12.58 am

 Natural product-derived combination therapy for blood-stage Plasmodium infection: A therapeutic mix encompassing Magnolol, Atovaquone,  and  Honokiol [MAH] decreases the expression of CTLA-4, PD-L1 and LAG-3, promotes CD4+ T-cell function, increases secretion of protective antibodies, promotes and clear blood-stage malaria via up regulation of its target gene, 17/October/2017, 12.50 am
October 16, 2017
Life-extension therapy: Triptolide, isolated from Thunder God Vine,  inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 17/October/2017, 10.52 pm
October 17, 2017
Show all

Significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


 

From Research findings to Therapeutic opportunity:

This study suggests, for the first time, a Xenon-based therapy for NAFLD. Xenon, by increasing the expression of its target gene, it may (1) promote degradation of HMGCR; and (2) suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol and total cholesterol levels; (2) attenuate lipid deposition in liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, Xenon may be used to treat NAFLD.

Figure 1. Mechanistic insights into how Xenon decreases the expression of HMGCR to prevent progression to NAFLD.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Xenon decrease the expression of HMGCR to prevent progression of NAFLD?

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org

* Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Xenon -based therapy for Non-alcoholic fatty liver disease (NAFLD): Xenon  promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 17/October/2017, 12.58 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.